Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

[HER2 and gastric cancer. Recommendations for clinical practice in 2011].

Penault-Llorca F, Chenard MP, Bouché O, Emile JF, Bibeau F, Metges JP, André T, Monges G.

Ann Pathol. 2011 Apr;31(2):78-87. doi: 10.1016/j.annpat.2011.03.001. Epub 2011 May 7. French.

PMID:
21601111
2.

HER2 testing in gastric cancer: a practical approach.

Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G.

Mod Pathol. 2012 May;25(5):637-50. doi: 10.1038/modpathol.2011.198. Epub 2012 Jan 6.

3.

HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).

Boers JE, Meeuwissen H, Methorst N.

Histopathology. 2011 Feb;58(3):383-94. doi: 10.1111/j.1365-2559.2011.03760.x. Epub 2011 Feb 16.

4.

[Her2 testing in gastric cancer. What is different in comparison to breast cancer?].

Rüschoff J, Nagelmeier I, Baretton G, Dietel M, Höfler H, Schildhaus HU, Büttner R, Schlake W, Stoss O, Kreipe HH.

Pathologe. 2010 May;31(3):208-17. doi: 10.1007/s00292-010-1278-1. German.

PMID:
20443098
5.

Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.

Fox SB, Kumarasinghe MP, Armes JE, Bilous M, Cummings MC, Farshid G, Fitzpatrick N, Francis GD, McCloud PI, Raymond W, Morey A.

Am J Surg Pathol. 2012 Apr;36(4):577-82. doi: 10.1097/PAS.0b013e318244adbb.

PMID:
22314190
6.

Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections.

Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MP.

Histopathology. 2011 Nov;59(5):832-40. doi: 10.1111/j.1365-2559.2011.04017.x.

PMID:
22092394
7.

[HER2 and gastric cancer: a novel therapeutic target for trastuzumab].

Bouché O, Penault-Llorca F.

Bull Cancer. 2010 Dec;97(12):1429-40. doi: 10.1684/bdc.2010.1224. Review. French.

PMID:
21134821
8.

Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.

Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks JB, Shah MA, Barbashina V.

Arch Pathol Lab Med. 2011 Nov;135(11):1460-5. doi: 10.5858/arpa.2010-0541-OA.

PMID:
22032573
9.

Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?

Park YS, Hwang HS, Park HJ, Ryu MH, Chang HM, Yook JH, Kim BS, Jang SJ, Kang YK.

Hum Pathol. 2012 Mar;43(3):413-22. doi: 10.1016/j.humpath.2011.05.019. Epub 2011 Aug 19.

PMID:
21855114
10.

Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.

Yan B, Yau EX, Choo SN, Ong CW, Yong KJ, Pang B, Salto-Tellez M.

J Clin Pathol. 2011 Oct;64(10):880-3. doi: 10.1136/jclinpath-2011-200009. Epub 2011 Jul 14.

PMID:
21757431
11.

Significance of accurate human epidermal growth factor receptor-2 (HER2) evaluation as a new biomarker in gastric cancer.

Kimura Y, Oki E, Yoshida A, Aishima S, Zaitsu Y, Ohtsu H, Ando K, Ida S, Saeki H, Morita M, Kusumoto T, Oda Y, Maehara Y.

Anticancer Res. 2014 Aug;34(8):4207-12.

PMID:
25075048
12.

Assessment of a HER2 scoring system for gastric cancer: results from a validation study.

Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T.

Histopathology. 2008 Jun;52(7):797-805. doi: 10.1111/j.1365-2559.2008.03028.x. Epub 2008 Apr 18.

PMID:
18422971
13.

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.

Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, Gardini G, Nizzoli R, Leonardi F, Gasparro D, Camisa R, Cavalli S, Silini EM, Ardizzoni A.

Br J Cancer. 2011 Apr 26;104(9):1372-6. doi: 10.1038/bjc.2011.121. Epub 2011 Apr 12. Erratum in: Br J Cancer. 2011 Jun 7;104(12):1929. Capelli, S [corrected to Cavalli, S].

14.

Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.

Im SA, Kim JW, Kim JS, Kim MA, Jordan B, Pickl M, Han SW, Oh DY, Lee HJ, Kim TY, Kim WH, Yang HK, Bang YJ.

Diagn Mol Pathol. 2011 Jun;20(2):94-100. doi: 10.1097/PDM.0b013e3181fc02b7.

PMID:
21532492
15.

HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.

Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Höfler H, Kreipe HH.

Virchows Arch. 2010 Sep;457(3):299-307. doi: 10.1007/s00428-010-0952-2. Epub 2010 Jul 28.

16.

Human epidermal growth-factor receptor 2 overexpression in gastric carcinoma in Thai patients.

Sornmayura P, Rerkamnuaychoke B, Jinawath A, Euanorasetr C.

J Med Assoc Thai. 2012 Jan;95(1):88-95.

PMID:
22379747
17.

HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer.

Gómez-Martin C, Garralda E, Echarri MJ, Ballesteros A, Arcediano A, Rodríguez-Peralto JL, Hidalgo M, López-Ríos F.

J Clin Pathol. 2012 Aug;65(8):751-7. doi: 10.1136/jclinpath-2012-200774. Epub 2012 May 8.

18.

HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options.

Koltz BR, Hicks DG, Whitney-Miller CL.

Biotech Histochem. 2012 Jan;87(1):40-5. doi: 10.3109/10520295.2011.591830. Epub 2011 Jul 12. Review.

PMID:
21745161
19.

Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.

Wang T, Hsieh ET, Henry P, Hanna W, Streutker CJ, Grin A.

Hum Pathol. 2014 May;45(5):970-5. doi: 10.1016/j.humpath.2013.12.010. Epub 2014 Jan 8.

PMID:
24656529
20.

Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.

Gumusay O, Benekli M, Ekinci O, Baykara M, Ozet A, Coskun U, Demirci U, Uner A, Dursun A, Atak EY, Buyukberber S.

Jpn J Clin Oncol. 2015 May;45(5):416-21. doi: 10.1093/jjco/hyv020. Epub 2015 Mar 2.

Items per page

Supplemental Content

Write to the Help Desk